Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2020 Sep 3

PMID 32877568

Citations 11

Authors

Sandra A Springer

Joshua A Barocas

Alysse Wurcel

Ank Nijhawan

Kinna Thakarar

Ruth Lynfield

Hermione Hurley

Jessica Snowden

Alice Thornton

Carlos Del Rio

Affiliations

Soon will be listed here.

Abstract

In response to the opioid crisis, IDSA and HIVMA established a working group to drive an evidence- and human rights-based response to illicit drug use and associated infectious diseases. Infectious diseases and HIV physicians have an opportunity to intervene, addressing both conditions. IDSA and HIVMA have developed a policy agenda highlighting evidence-based practices that need further dissemination. This paper reviews (1) programs most relevant to infectious diseases in the 2018 SUPPORT Act; (2) opportunities offered by the "End the HIV Epidemic" initiative; and (3) policy changes necessary to affect the trajectory of the opioid epidemic and associated infections. Issues addressed include leveraging harm reduction tools and improving integrated prevention and treatment services for the infectious diseases and substance use disorder care continuum. By strengthening collaborations between infectious diseases and addiction specialists, including increasing training in substance use disorder treatment among infectious diseases and addiction specialists, we can decrease morbidity and mortality associated with these overlapping epidemics.

Citing Articles

Infectious Diseases Fellowship Training in Caring for People Who Use Drugs: A National Assessment of an Emerging Training Need.

Vasishta S, Jawa R, Kurz S, Nolan N Open Forum Infect Dis. 2024; 11(10):ofae544.

PMID: 39411220 PMC: 11474980. DOI: 10.1093/ofid/ofae544.

HIV and Substance Use Disorders.

Lier A, Tarfa A, Shenoi S, Kuo I, Springer S Infect Dis Clin North Am. 2024; 38(3):599-611.

PMID: 38960783 PMC: 11410345. DOI: 10.1016/j.idc.2024.06.003.

Considerations when prescribing opioid agonist therapies for people living with HIV.

Tarfa A, Lier A, Shenoi S, Springer S Expert Rev Clin Pharmacol. 2024; 17(7):549-564.

PMID: 38946101 PMC: 11299801. DOI: 10.1080/17512433.2024.2375448.

Integrated Care Models: HIV and Substance Use.

Hill K, Kuo I, Shenoi S, Desruisseaux M, Springer S Curr HIV/AIDS Rep. 2023; 20(5):286-295.

PMID: 37698755 PMC: 11034717. DOI: 10.1007/s11904-023-00667-9.

Partial-Oral Antibiotic Therapy for Bone and Joint Infections in People With Recent Injection Drug Use.

Yang W, Dombrowski J, Glick S, Kim H, Beieler A, Lan K Open Forum Infect Dis. 2023; 10(1):ofad005.

PMID: 36726538 PMC: 9887258. DOI: 10.1093/ofid/ofad005.

References

Evans M, Labuda S, Hogan V, Agnew-Brune C, Armstrong J, Periasamy Karuppiah A . Notes from the Field: HIV Infection Investigation in a Rural Area - West Virginia, 2017. MMWR Morb Mortal Wkly Rep. 2018; 67(8):257-258. PMC: 5861700. DOI: 10.15585/mmwr.mm6708a6. View

Midboe A, Byrne T, Smelson D, Jasuja G, McInnes K, Troszak L . The Opioid Epidemic In Veterans Who Were Homeless Or Unstably Housed. Health Aff (Millwood). 2019; 38(8):1289-1297. DOI: 10.1377/hlthaff.2019.00281. View

Meinhofer A, Witman A . The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion. J Health Econ. 2018; 60:177-197. DOI: 10.1016/j.jhealeco.2018.06.004. View

McManus K, Christensen B, Nagraj V, Furl R, Yerkes L, Swindells S . Evidence From a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans' Association With Viral Suppression. Clin Infect Dis. 2019; 71(10):2572-2580. PMC: 7744983. DOI: 10.1093/cid/ciz1123. View

Kerr T, Stoltz J, Tyndall M, Li K, Zhang R, Montaner J . Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ. 2006; 332(7535):220-2. PMC: 1352057. DOI: 10.1136/bmj.332.7535.220. View

Hennessey K, Kim A, Griffin V, Collins N, Weinbaum C, Sabin K . Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health. 2008; 86(1):93-105. PMC: 2629523. DOI: 10.1007/s11524-008-9305-8. View

Springer S, Spaulding A, Meyer J, Altice F . Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis. 2011; 53(5):469-79. PMC: 3156144. DOI: 10.1093/cid/cir446. View

Golden M, Lechtenberg R, Glick S, Dombrowski J, Duchin J, Reuer J . Outbreak of Human Immunodeficiency Virus Infection Among Heterosexual Persons Who Are Living Homeless and Inject Drugs - Seattle, Washington, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(15):344-349. PMC: 6476056. DOI: 10.15585/mmwr.mm6815a2. View

Jackson K, Bohm M, Brooks J, Asher A, Nadle J, Bamberg W . Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs - Six Sites, 2005-2016. MMWR Morb Mortal Wkly Rep. 2018; 67(22):625-628. PMC: 5991809. DOI: 10.15585/mmwr.mm6722a2. View

10.

Jones C . Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S. Int J Drug Policy. 2019; 70:22-32. DOI: 10.1016/j.drugpo.2019.04.006. View

11.

Wood E, Tyndall M, Zhang R, Stoltz J, Lai C, Montaner J . Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006; 354(23):2512-4. DOI: 10.1056/NEJMc052939. View

12.

Brinkley-Rubinstein L, Dauria E, Tolou-Shams M, Christopoulos K, Chan P, Beckwith C . The Path to Implementation of HIV Pre-exposure Prophylaxis for People Involved in Criminal Justice Systems. Curr HIV/AIDS Rep. 2018; 15(2):93-95. PMC: 5884709. DOI: 10.1007/s11904-018-0389-9. View

13.

Ruhm C . Nonopioid Overdose Death Rates Rose Almost As Fast As Those Involving Opioids, 1999-2016. Health Aff (Millwood). 2019; 38(7):1216-1224. DOI: 10.1377/hlthaff.2018.05522. View

14.

Akiyama M, Columbus D, MacDonald R, Jordan A, Schwartz J, Litwin A . Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial. BMC Infect Dis. 2019; 19(1):703. PMC: 6686449. DOI: 10.1186/s12879-019-4344-1. View

15.

Barocas J, Beiser M, Leon C, Gaeta J, OConnell J, Linas B . Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults. JAMA Intern Med. 2017; 177(6):880-882. PMC: 5575839. DOI: 10.1001/jamainternmed.2017.0358. View

16.

Zaller N, Brinkley-Rubinstein L . Incarceration, drug use, and infectious diseases: a syndemic still not addressed. Lancet Infect Dis. 2018; 18(12):1301-1302. DOI: 10.1016/S1473-3099(18)30538-3. View

17.

Wakeman S, McKinney M, Rich J . Filling the gap: the importance of Medicaid continuity for former inmates. J Gen Intern Med. 2009; 24(7):860-2. PMC: 2695526. DOI: 10.1007/s11606-009-0977-x. View

18.

Beiser M, Smith K, Ingemi M, Mulligan E, Baggett T . Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy. 2019; 72:129-137. DOI: 10.1016/j.drugpo.2019.03.017. View

19.

Marks L, Munigala S, Warren D, Liang S, Schwarz E, Durkin M . Addiction Medicine Consultations Reduce Readmission Rates for Patients With Serious Infections From Opioid Use Disorder. Clin Infect Dis. 2018; 68(11):1935-1937. PMC: 6522678. DOI: 10.1093/cid/ciy924. View

20.

Springer S, Korthuis P, Del Rio C . Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. Ann Intern Med. 2018; 169(5):335-336. PMC: 6251491. DOI: 10.7326/M18-1203. View